Every Form 4 that OKYO Pharma Limited (OKYO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OKYO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OKYO filings page.
OKYO Pharma Ltd director John P. Brancaccio reported an open-market purchase of 5,000 shares of common stock on July 21, 2026 at $1.477 per share. Following this trade, he directly owns 35,201 shares.
The amended insider report corrects the transaction code for this purchase and indicates the trade was not made under a Rule 10b5-1 trading plan.
OKYO Pharma Ltd reported that Chief Executive Officer Robert John Dempsey purchased 15,000 shares of common stock on July 22, 2026 at $1.539 per share in a transaction coded as a purchase in an open market or private transaction. Following this trade, he directly holds 15,000 shares. The Form 4/A states it amends the July 23, 2026 filing solely to correct the transaction code, with no other transactions affected and the Rule 10b5-1 trading-plan box left unchecked.
OKYO Pharma Ltd reported an amended insider transaction for Chief Development Officer Gary S Jacob. The amendment only corrects the code for an open market purchase on July 21, 2026, when he bought 3,500 common shares at $1.40, increasing his direct holdings to 112,420 shares.
OKYO Pharma Ltd reported that director and ten percent owner Gabriele M Cerrone, through Panetta Partners Limited, purchased 22,500 shares of common stock on July 21, 2026 in an open-market transaction at $1.45 per share. After this indirect purchase, the associated entity holds 10,873,916 common shares. This amended filing solely corrects the transaction code and reflects a trade not made under a Rule 10b5-1 plan.
OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, purchased 25,000 shares of common stock in an open market transaction on July 20, 2026 at $1.40 per share, increasing his indirect holdings to 10,851,416 shares. This amendment corrects the transaction code for that purchase; no other transactions are changed.
OKYO Pharma Ltd disclosed that Chief Medical Officer Flavio Mantelli purchased 20,000 shares of common stock in an open-market transaction on July 21, 2026 at $1.40 per share, resulting in direct holdings of 20,000 shares. This Form 4/A filing solely corrects the transaction code on the earlier report; no other transactions are changed.
OKYO Pharma Ltd reported that Chief Scientific Officer Rajkumar V. Patil made an open market purchase of 3,363 shares of common stock on July 27, 2026 at $1.49 per share. Following this transaction, he directly owns 20,030 shares. This Form 4/A corrects only the transaction code, and the transaction was not reported under a Rule 10b5-1 trading plan.
Patil Rajkumar V. reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd reported that Chief Scientific Officer Rajkumar V. Patil received a grant of 3,363 shares of common stock on July 27, 2026, at $1.49 per share. Following this award, he directly owns 20,030 shares of OKYO Pharma common stock.
OKYO Pharma Ltd reported that CEO Robert John Dempsey received a grant or award of 15,000 shares of common stock on July 22, 2026 at a reported value of $1.539 per share. Following this non-derivative acquisition, he directly holds 15,000 common shares. The transaction was not made under a Rule 10b5-1 trading plan.
CERRONE GABRIELE M reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd reported that director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, received a grant/award of 22,500 common shares on 2026-07-21 at 1.45 per share. Following this award, his indirect holdings total 10,873,916 common shares.
JACOB GARY S reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd reported that Chief Development Officer Gary S Jacob received a grant of 3,500 shares of common stock on July 21, 2026, at $1.40 per share. After this non-derivative grant, he directly owns 112,420 common shares. The award was not made under a Rule 10b5-1 trading plan.
OKYO Pharma Ltd director John P Brancaccio reported a grant of 5000 shares of common stock on 2026-07-21. The award, coded as a “grant, award, or other acquisition,” was priced at $1.4770 per share and increased his direct holdings to 35201 shares. The filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.
Mantelli Flavio reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd’s chief medical officer, Flavio Mantelli, received a grant of 20,000 shares of common stock on July 21, 2026. The award was recorded at $1.40 per share as direct ownership, and Mantelli now directly holds 20,000 shares of OKYO Pharma common stock.
OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, reported a grant/award acquisition of 25,000 shares of common stock at $1.40 per share on July 20, 2026. Following this indirect transaction, his reported holdings via that entity are 10,851,416 shares.
OKYO Pharma director Bernard Denoyer received an option grant for 3,500 shares of OKYO Pharma Ltd common shares. The options have an exercise price of $1.85 per share and are exercisable into 3,500 common shares. After this grant, Denoyer holds options on 35,190 shares in total. The options are scheduled to expire on June 8, 2036, indicating a long-dated, compensation-related award rather than an open-market share purchase or sale.
OKYO Pharma Ltd director John P. Brancaccio received a grant of options over 6,500 common shares at an exercise price of $1.85 per share. These options were awarded on June 8, 2026 and are scheduled to become exercisable on June 8, 2027, expiring on June 8, 2036. Following this compensation-related grant, Brancaccio holds options over 138,394 shares in total.
OKYO Pharma Ltd director Simon Willy Jules received a grant of options over 6,500 common shares at an exercise price of $1.85 per share. These options relate to common shares and increase his directly held derivative position to 135,502 options following the transaction. The options become exercisable on June 8, 2027 and are scheduled to expire on June 8, 2036, indicating a long-term, compensation-related award rather than an open-market share purchase or sale.
OKYO Pharma Ltd reported that Chief Financial Officer Keeren Rameshchandra Shah received a grant of options covering 40,000 common shares at an exercise price of $1.85 per share. These options are exercisable beginning on June 8, 2027 and expire on June 8, 2036. Following this award, the filing shows 544,819 derivative securities held directly, indicating this is a compensation-related grant rather than an open-market purchase.
OKYO Pharma Ltd director and 10% owner Gabriele M. Cerrone reported an indirect acquisition of 300,000 shares of common stock. The shares were received as a grant or award at a reference price of $1.72 per share and are held through Panetta Partners Limited.
Following this transaction, indirect holdings associated with Cerrone total 10,826,416 shares of OKYO Pharma common stock, indicating this was a relatively small addition to an already large position.